Related Experiment Video
Updated: Jun 4, 2026

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
Subthalamic deep brain stimulation increases pallidal firing rate and regularity.
René Reese1, Arthur Leblois, Frank Steigerwald
1Department of Neurology, University Hospitals Schleswig-Holstein, Kiel, Germany.
Experimental Neurology
|February 10, 2011
Summary
High-frequency stimulation of the subthalamic nucleus (STN-HFS) improves Parkinson's disease (PD) by altering pallidal neuron activity. This deep brain stimulation normalizes firing patterns, contributing to therapeutic effects.
Area of Science:
- Neuroscience
- Neurology
- Neurosurgery
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder impacting motor control.
- High-frequency stimulation of the subthalamic nucleus (STN-HFS) is an effective treatment for PD motor symptoms.
- The precise neural mechanisms underlying STN-HFS efficacy remain incompletely understood.
Purpose of the Study:
- To investigate the effects of STN-HFS on single-neuron activity in the pallidum of a PD patient.
- To elucidate the cellular-level changes in pallidal output during therapeutic STN-HFS.
Main Methods:
- Recording of single-neuron activity in the globus pallidus during STN-HFS in a patient with Parkinson's disease.
- Analysis of firing rate, response patterns to stimulation pulses, and firing regularity of pallidal neurons.
Main Results:
- STN-HFS significantly increased the firing rate of pallidal neurons in both segments of the globus pallidus.
- Pallidal neurons exhibited time-locked responses to individual stimulation pulses, characterized by early excitation, followed by inhibition, and a late excitation.
- STN-HFS led to increased firing regularity in pallidal neurons.
Conclusions:
- The observed time-locked responses and enhanced firing regularity during STN-HFS suggest a mechanism for overriding abnormal pallidal activity in PD.
- These changes in pallidal neuronal function likely contribute significantly to the therapeutic benefits of STN-HFS in Parkinson's disease treatment.

